WallStSmart

Abbott Laboratories (ABT)vsElectrocore LLC (ECOR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 125921% more annual revenue ($46.59B vs $36.97M). ABT leads profitability with a 11.7% profit margin vs -40.0%. ABT earns a higher WallStSmart Score of 54/100 (C-).

ABT

Buy

54

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

ECOR

Avoid

24

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 6.7Quality: 5.0
Piotroski: 3/9Altman Z: -14.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-37.5%)

Margin of Safety

-37.5%

Fair Value

$74.13

Current Price

$101.95

$27.82 premium

UndervaluedFair: $74.13Overvalued
ECORUndervalued (+82.8%)

Margin of Safety

+82.8%

Fair Value

$31.76

Current Price

$9.62

$22.14 discount

UndervaluedFair: $31.76Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$176.41B9/10

Large-cap with strong market position

Free Cash FlowQuality
$2.09B8/10

Generating 2.1B in free cash flow

ECOR2 strengths · Avg: 9.0/10
Debt/EquityHealth
-3.4310/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
28.0%8/10

Revenue surging 28.0% year-over-year

Areas to Watch

ABT3 concerns · Avg: 3.3/10
PEG RatioValuation
1.904/10

Expensive relative to growth rate

P/E RatioValuation
33.4x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-47.5%2/10

Earnings declined 47.5%

ECOR4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$81.59M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-478.7%2/10

ROE of -478.7% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Free Cash Flow. Revenue growth of 13.0% demonstrates continued momentum.

Bull Case : ECOR

The strongest argument for ECOR centers on Debt/Equity, Revenue Growth. Revenue growth of 28.0% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.

Bear Case : ECOR

The primary concerns for ECOR are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

ABT profiles as a value stock while ECOR is a growth play — different risk/reward profiles.

ECOR carries more volatility with a beta of 0.94 — expect wider price swings.

ECOR is growing revenue faster at 28.0% — sustainability is the question.

ABT generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

ABT scores higher overall (54/100 vs 24/100) and 13.0% revenue growth. ECOR offers better value entry with a 82.8% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Electrocore LLC

HEALTHCARE · MEDICAL DEVICES · USA

electroCore, Inc., a commercial-stage medical device company, is dedicated to the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is headquartered in Rockaway, New Jersey.

Want to dig deeper into these stocks?